Utah Medical Products (UTMD) AI Stock Analysis

• Market Cap: $187.75M
• Dividend Yield: 2.11%
• Average Volume (3M): 16.98K
• Price to Earnings (P/E): 15.3
• Beta (1Y): 0.52
• Revenue Growth: -19.92%
• EPS Growth: -16.22%
• Country: US
• Employees: 155
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 3.78
• Shares Outstanding: 3,248,210
• 10 Day Avg. Volume: 30,241
• 30 Day Avg. Volume: 16,982
• PEG Ratio: 1.87
• Price to Book (P/B): 3.20
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 17.99
• Enterprise Value/Market Cap: 1.55
• Enterprise Value/Revenue: 1.61
• Enterprise Value/Gross Profit: 12.31
• Enterprise Value/Ebitda: 3.78
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 79 Outperform
• Price Target: $64.00 ▲(10.73%Upside)

Utah Medical Products showcases strong financial health with a solid balance sheet and profitability. While technical indicators suggest a moderate positive momentum, the company's valuation is attractive with a reasonable P/E ratio and a decent dividend yield. These factors collectively result in a strong overall stock score.

Utah Medical Products Business Overview & Revenue Model

Company Description

Utah Medical Products, Inc. (UTMD) is a company that designs, manufactures, and markets a broad range of medical devices used in healthcare facilities. The company primarily serves the obstetrics, gynecology, neonatal care, and critical care sectors. UTMD's core products include devices for labor and delivery, neonatal intensive care, and gynecological procedures, focusing on improving patient outcomes and reducing healthcare costs.

How the Company Makes Money

Utah Medical Products generates revenue through the sale of its medical devices to hospitals, clinics, and other healthcare providers. The company's key revenue streams include direct sales of its products, as well as through distributors and original equipment manufacturers (OEMs). UTMD's earnings are significantly supported by its focus on niche markets where it offers specialized, high-quality devices that meet specific clinical needs. Additionally, the company may benefit from strategic partnerships and collaborations that enhance its market reach and product offerings.

Utah Medical Products Financial Statement Overview

Summary

Utah Medical Products presents a strong financial profile with excellent profitability and a robust balance sheet. The company has maintained healthy margins and low leverage, which positions it well for stability and potential growth. However, the recent decline in revenue and operating cash flow could pose challenges if not addressed. Overall, the company remains financially sound, with opportunities to enhance revenue growth and cash flow management.

Income Statement

Utah Medical Products has demonstrated strong profitability with a consistent gross profit margin averaging around 60% and net profit margins exceeding 30% in recent years. However, the company experienced a decline in revenue growth in the latest year, showing a decrease in total revenue from $52.28 million in 2022 to $50.22 million in 2023. Despite this, the EBIT and EBITDA margins have remained robust, indicating efficient operations.

Balance Sheet

The company exhibits a strong balance sheet with a low debt-to-equity ratio close to 0, reflecting minimal leverage. The return on equity has been impressive, supported by solid net income figures. The equity ratio is high, indicating a stable financial structure with a significant portion of assets financed by equity, minimizing financial risk.

Cash Flow

Cash flow analysis shows mixed results. While the company has consistently generated positive free cash flow, there was a notable decline in operating cash flow from $22.28 million in 2023 to $0 in 2024. This abrupt change suggests potential operational challenges or shifts in cash management strategies. Despite this, the historical consistency in free cash flow generation indicates underlying financial health.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	40.90M	50.22M	52.28M	49.05M	42.18M
Gross Profit	24.14M	30.04M	32.20M	30.92M	25.55M
EBITDA	16.44M	24.75M	26.87M	26.16M	20.92M
Net Income	13.87M	16.64M	16.47M	14.79M	10.80M
Balance Sheet
Total Assets	122.54M	135.46M	123.87M	115.56M	111.75M
Cash, Cash Equivalents and Short-Term Investments	82.98M	92.87M	75.05M	60.97M	51.59M
Total Debt	282.00K	295.00K	341.00K	331.00K	335.00K
Total Liabilities	5.11M	7.14M	9.62M	8.42M	8.92M
Stockholders Equity	117.43M	128.31M	114.25M	107.14M	102.82M
Cash Flow
Free Cash Flow	0.00	21.64M	20.33M	20.65M	19.28M
Operating Cash Flow	0.00	22.28M	21.15M	21.20M	20.14M
Investing Cash Flow	0.00	-639.00K	-818.00K	-552.00K	-860.00K
Financing Cash Flow	0.00	-4.17M	-5.48M	-10.90M	-10.73M

Utah Medical Products Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 57.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UTMD, the sentiment is Positive. The current price of 57.8 is above the 20-day moving average (MA) of 55.56, above the 50-day MA of 54.12, and below the 200-day MA of 59.60, indicating a neutral trend. The MACD of 0.47 indicates Negative momentum. The RSI at 65.86 is Neutral, neither overbought nor oversold. The STOCH value of 82.46 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for UTMD.

Utah Medical Products Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UTMD	79 Outperform	$187.75M	15.30	10.59%	2.11%	-19.92%	-16.22%
INFU	76 Outperform	$128.37M	41.69	5.94%	―	7.98%	3304.55%
PDEX	67 Neutral	$146.36M	16.04	28.29%	―	29.65%	131.78%
STXS	63 Neutral	$196.94M	―	-179.82%	―	1.50%	-20.00%
Sector *	60 Neutral	HK$15.14B	5.55	-7.43%	4.78%	11.72%	-20.69%
OSUR	57 Neutral	$225.15M	25.27	-7.77%	―	-46.95%	-237.44%
SMTI	44 Neutral	$252.50M	―	-28.58%	―	34.65%	-128.56%